GSK in $40 million Paxil settlement with US health payers
This article was originally published in Scrip
Executive Summary
In a settlement approved in US District Court in Minneapolis, GlaxoSmithKlinehas agreed to pay $40 million to third-party payers who claimed in a class action suit that GSK promoted the use of Paxil (paroxetine) in children and teenagers while withholding and concealing negative information on the efficacy and safety of the product. GSK has denied the claims.